This internet activity is based on highlights from a symposium held at the CCFA Annual Meeting (Friday, December 5th, 2014).

Statement of Need

As the pathogenesis and natural history of Crohn's disease becomes better understood there is considerable interest in the emerging ability to stratify patients with CD to better reflect the different phenotypes. Notably, as disease progresses to a less inflammatory and more structuring disease, current therapies may be less effective. Prognostic factors which may have clinical application now, or in the near future, include serologic, clinical, and genetic markers, and there is now potential to use some of these to better individualize therapy including, for patients with more severe disease, a more aggressive management strategy which might include "step-in" or an "accelerated step-up" approach. For these patients earlier initiation of biologic therapy may improve long-term outcomes.

Target Audience

This activity has been designed to meet the educational needs of gastroenterologists and registered nurses involved in the care of patients with inflammatory bowel disease (IBD).

Release Date: February 1, 2015
Expiration Date: February 1, 2016

Learning Objectives

After completing this activity, the participant should be better able to:

  • Summarize the current evidence for predictive markers of progression in Crohn's disease (CD)
  • State the clinical and biologic markers associated with response/non-response to therapy in moderate-severe CD
  • Evaluate whether this information can be used in clinical management, including tailoring therapy to optimize therapeutic outcomes, and if so how
  • Provide appropriate care and counsel for patients and their families.

Estimated Time to Complete Activity: 30 minutes

Faculty

Maria T. Abreu, MD (Course Director)
Professor of Medicine
Professor of Microbiology and Immunology
Chief, Division of Gastroenterology
Martin Kalser Chair in Gastroenterology
Director, Crohn's & Colitis Center
University of Miami Miller School of Medicine
Miami, FL



Marla C. Dubinsky, MD
Professor of Pediatrics
Chief, Pediatric Gastroenterology, Hepatology and Nutrition
Co-Director, Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center
Icahn School of Medicine, Mount Sinai Hospital
New York, NY





William J. Sandborn, MD
Chief, Division of Gastroenterology
University of California San Diego
San Diego, CA







Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter

Reported Financial Relationship

Maria T. Abreu, MD

Consulting: AbbVie Laboratories, Asana Medical, Inc., Ferring Pharmaceuticals, Focus Medical Communications, GSK Holding Americas, Inc., Hospira, Inc., Janssen, Mucosal Health Board, Pfizer, Prometheus Labs, Salix Pharmaceuticals, Inc., Sanofi Aventi, Shire Pharmaceuticals, Takeda, UCB

Non-CME/CE: AbbVie Laboratories, Focus Medical Communications, GI Health Foundation, Prova Education, Inc., UEGW Israeli Physicians Group, WebMD Health

Other: AbbVie Laboratories, GI Health Foundation, Janssen, Pfizer, Prometheus Labs, Sanofi Aventi, Takeda, UCB

Marla C. Dubinsky, MD

Consulting: AbbVie Laboratories, Avaxia, Genentech, Janssen, Prometheus Labs, Salix, Shire Pharmaceuticals, Takeda, UCB

William J. Sandborn, MD

Consulting: AbbVie Laboratories, Janssen, Prometheus Labs, Takeda, UCB

Contracted Research: AbbVie Laboratories, Janssen, Prometheus Labs, Takeda, UCB

Non-CME/CE: Takeda

The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

The following PIM planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CCMEP, and Jan Schultz, RN, MSN, CCMEP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

The following SCI planners and managers, Ian Morgan, MSc, and Elena Urso, BSc, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity or any amount during the past 12 months.

Physician Continuing Medical Education

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Strategic Consultants International. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation
This educational activity for 0.5 contact hours is provided by Postgraduate Institute for Medicine.

Accreditation Statement
Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

How to Obtain Credit

There are no fees for participating and receiving CME/CE credit for this activity. To successfully earn credit, participants must complete the activity online during the valid credit period. Follow these steps to earn CME/CE credit:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the online educational content
  3. Once the activity is complete, complete the online posttest, and the online evaluation.

Upon successful completion of the posttest, with a passing score of 75% or better, and the online Evaluation form, you will have immediate access to a CME/CE certificate to print or save for your files.

If you have any questions regarding the CME/CE certification for this activity, please contact Postgraduate Institute for Medicine at: information@pimed.com or (303) 799-1930.

Media: Internet

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

This activity is supported by an educational grant from UCB, Inc.

 
This activity is jointly provided by
Postgraduate Institute for Medicine and Strategic Consultants International.